Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 143-150

  Lu, Huading ^a   Lian, Liyi ^a   Shi, Dehai ^a   Zhao, Huiqing ^a   Dai, Yuhu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Activated protein kinase P38; Bone morphogenetic protein small mothers against decapentaplegic; Hepcidin; Mitogen; Osteogenic differentiation

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DECAPENTAPLEGIC PROTEIN; HEPCIDIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SMAD PROTEIN;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENETIC TRANSFECTION; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; HEPCIDINS; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOGENESIS; RATS; SMAD PROTEINS;

EID: 84916232307     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2769     Document Type: Article

References (33)

1. Kanis JA and Reginster JY: European guidance for the diagnosis and management of osteoporosis in postmenopausal women-what is the current message for clinical practice? Pol Arch Med Wewn 118: 538-540, 2008.
2. Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: now and the future. Lancet 377: 1276-1287, 2011.
3. Ma B, Liu J, Zhang Q, Ying H, A J, Sun J, Wu D, Wang Y, Li J and Liu Y: Metabolomic profles delineate signature metabolic shifts during estrogen defciency-induced bone loss in rat by GC-TOF/MS. PLoS One 8: e54965, 2013.
4. de Lignieres B: Hormone replacement therapy: clinical benefts and side-effects. Maturitas 23: S31-S36, 1996.
5. Fournier A, Berrino F, Riboli E, Avenel V and Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448-454, 2005.
6. Beral V, Million Women Study Collaborators, Bull D, Green J and Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703-1710, 2007.
7. Furness S, Roberts H, Marjoribanks J and Lethaby A: Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 8: CD000402, 2012.
8. Li GF, Pan YZ, Sirois P, Li K and Xu YJ: Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int 23: 2403-2408, 2012.
9. Weinberg ED: Iron loading: a risk factor for osteoporosis. Biometals 19: 633-635, 2006.
10. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S and Sinigaglia L: Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20: 549-555, 2009.
11. Weinberg ED: Role of iron in osteoporosis. Pediatr Endocrinol Rev 6: 81-85, 2008.
12. Roussou P, Tsagarakis NJ, Kountouras D, Livadas S and Diamanti-Kandarakis E: Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. Anemia 2013: 617204, 2013.
13. Sun L, Guo W, Yin C, Zhang S, Qu G, Hou Y, Rong H, Ji H and Liu S: Hepcidin defciency undermines bone load-bearing capacity through inducing iron overload. Gene 543: 161-165, 2014.
14. Sun CC, Vaja V, Babitt JL and Lin HY: Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of infammation. Am J Hematol 87: 392-400, 2012.
15. Mascitelli L and Goldstein MR: Hereditary hemochromatosis, iron, hepcidin, and coronary heart disease. Med Hypotheses 82: 402-403, 2014
16. Zucker S: The swinging pendulum of the anemia of cancer: erythropoietin trumps hepcidin. J Clin Oncol 29: e42, 2011.
17. Canavesi E, Alferi C, Pelusi S and Valenti L Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 1: 166-176, 2012.
18. Xu Y, Li G, Du B, Zhang P, Xiao L, Sirois P and Li K: Hepcidin increases intracellular Ca2+ of osteoblast hFOB1.19 through L-type Ca2+ channels. Regul Pept 172: 58-61, 2011.
19. Ku HK, Lim HM, Oh KH, Yang HJ, Jeong JS and Kim SK: Interpretation of protein quantitation using the Bradford assay: comparison with two calculation models. Anal Biochem 434: 178-180, 2013.
20. Zhang P, Xu YJ, Zhao DY, Ma Y, Xiao L, Feng YS, Du BC, Qian ZM and Li K: Increased intracellular iron and mineralization of cultured hFOB 1.19 cells following hepcidin activation through ferroportin-1. Saudi Med J 31: 1303-1308, 2010.
21. Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM and Cho YS: Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 19: 557-568, 2010.
22. Kim do Y, Kim GW and Chung SH: Nectandrin A Enhances the BMP-Induced Osteoblastic Differentiation and Mineralization by Activation of p38 MAPK-Smad Signaling Pathway. Korean J Physiol Pharmacol 17: 447-453, 2013.
23. Kim do Y, Jung MS, Park YG, Yuan HD, Quan HY and Chung SH: Ginsenoside Rh2(S) induces the differentiation and mineralization of osteoblastic MC3T3-E1 cells through activation of PKD and p38 MAPK pathways. BMB Rep 44: 659-664, 2011.
24. Chamberlain G, Fox J, Ashton B and Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25: 2739-2749, 2007
25. Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D and Anderson GJ: Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 123: 835-844, 2002.
26. Sasaki Y, Shimonaka Y, Ikuta K, Hosoki T, Sasaki K Torimoto Y, Kanada H, Moriguchi Y and Kohgo Y Hepcidin production in response to iron is controlled by monocyte-derived humoral factors. Int J Hematol 99: 12-20, 2014
27. Dai J, Li Y, Zhou H, Chen J, Chen M and Xiao Z: Genistein promotion of osteogenic differentiation through BMP/SMAD5/RUNX2 signaling. Int J Biol Sci 9: 1089-1098, 2013.
28. Liao QC, Xiao ZS, Qin YF and Zhou HH: Genistein stimulates osteoblastic differentiation via p38 MAPK-Cbfal pathway in bone marrow culture. Acta Pharmacol Sin 28: 1597-1602, 2007
29. Li GF, Xu YJ, He YF, Du BC, Zhang P, Zhao DY, Yu C, Qin CH and Li K: Effect of hepcidin on intracellular calcium in human osteoblasts. Mol Cell Biochem 366: 169-174, 2012.
30. Chen Z, Wu C, Gu W, Klein T, Crawford R and Xiao Y Osteogenic differentiation of bone marrow MSCs by β-tricalcium phosphate stimulating macrophages via BMP2 signalling pathway. Biomaterials 35: 1507-1518, 2014
31. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V and Ganz T: Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4 Blood 110: 2182-2189, 2007
32. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC and Lin HY: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38: 531-539, 2006.
33. Liu Y, Zheng WK, Gao WS, Shen Y and Ding WY Function of TGF-beta and p38 MAKP signaling pathway in osteoblast differentiation from rat adipose-derived stem cells. Eur Rev Med Pharmacol Sci 17: 1611-1619, 2013.